- Home
- OBIO vs SANG Comparison
OBIO vs SANG Comparison
Compare OBIO & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- SANG
- Stock Information
- Founded
- OBIO 2017
- SANG 1984
- Country
- OBIO United States
- SANG Canada
- Employees
- OBIO N/A
- SANG N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- SANG Computer Software: Programming Data Processing
- Sector
- OBIO Health Care
- SANG Technology
- Exchange
- OBIO Nasdaq
- SANG Nasdaq
- Market Cap
- OBIO 198.2M
- SANG 212.3M
- IPO Year
- OBIO N/A
- SANG 2021
- Fundamental
- Price
- OBIO $4.72
- SANG $5.82
- Analyst Decision
- OBIO Strong Buy
- SANG
- Analyst Count
- OBIO 4
- SANG 0
- Target Price
- OBIO $16.25
- SANG N/A
- AVG Volume (30 Days)
- OBIO 50.3K
- SANG 11.7K
- Earning Date
- OBIO 03-26-2025
- SANG 02-05-2025
- Dividend Yield
- OBIO N/A
- SANG N/A
- EPS Growth
- OBIO N/A
- SANG N/A
- EPS
- OBIO N/A
- SANG N/A
- Revenue
- OBIO $2,647,000.00
- SANG $241,243,000.00
- Revenue This Year
- OBIO $22.61
- SANG N/A
- Revenue Next Year
- OBIO $16.64
- SANG $3.21
- P/E Ratio
- OBIO N/A
- SANG N/A
- Revenue Growth
- OBIO N/A
- SANG N/A
- 52 Week Low
- OBIO $3.96
- SANG $3.78
- 52 Week High
- OBIO $8.87
- SANG $7.99
- Technical
- Relative Strength Index (RSI)
- OBIO 38.59
- SANG 33.78
- Support Level
- OBIO $5.20
- SANG $6.17
- Resistance Level
- OBIO $5.98
- SANG $6.43
- Average True Range (ATR)
- OBIO 0.42
- SANG 0.36
- MACD
- OBIO -0.07
- SANG -0.11
- Stochastic Oscillator
- OBIO 2.70
- SANG 23.79
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.